ChromaDex to Present at the 37th Annual Roth Conference
ChromaDex (NASDAQ: CDXC), a leader in NAD+ science and healthy aging, has announced its participation in the 37th Annual ROTH Conference. CEO Rob Fried will be featured on the Longevity and Supplementation Panel on Monday, March 17, at 12:00 PM PT.
The conference will include various engagement formats such as one-on-one meetings, analyst-selected fireside chats, and industry panels. Both CEO Rob Fried and CFO Ozan Pamir will conduct in-person meetings with institutional investors during the event.
The conference will showcase approximately 450 private and public companies across multiple growth sectors, including Healthcare, Technology, Business Services, Consumer, Industrial Growth, Sustainability, and more. The Longevity and Supplementation Panel will be accessible via livestream at wsw.com/webcast/roth50.
ChromaDex (NASDAQ: CDXC), un leader nella scienza del NAD+ e nell'invecchiamento sano, ha annunciato la sua partecipazione al 37° Annual ROTH Conference. Il CEO Rob Fried sarà presente al Pannello sulla Longevità e Supplementazione lunedì 17 marzo, alle 12:00 PT.
La conferenza includerà vari formati di coinvolgimento, come incontri one-to-one, chiacchierate selezionate dagli analisti e pannelli di settore. Sia il CEO Rob Fried che il CFO Ozan Pamir condurranno incontri di persona con investitori istituzionali durante l'evento.
La conferenza presenterà circa 450 aziende private e pubbliche provenienti da diversi settori in crescita, tra cui Sanità, Tecnologia, Servizi Aziendali, Consumo, Crescita Industriale, Sostenibilità e altro ancora. Il Pannello sulla Longevità e Supplementazione sarà accessibile tramite livestream su wsw.com/webcast/roth50.
ChromaDex (NASDAQ: CDXC), un líder en la ciencia del NAD+ y el envejecimiento saludable, ha anunciado su participación en la 37ª Conferencia Anual ROTH. El CEO Rob Fried será presentado en el Panel de Longevidad y Suplementación el lunes 17 de marzo a las 12:00 PM PT.
La conferencia incluirá varios formatos de participación, como reuniones uno a uno, charlas junto a la chimenea seleccionadas por analistas y paneles de la industria. Tanto el CEO Rob Fried como el CFO Ozan Pamir llevarán a cabo reuniones en persona con inversores institucionales durante el evento.
La conferencia mostrará aproximadamente 450 empresas privadas y públicas de múltiples sectores en crecimiento, incluyendo Salud, Tecnología, Servicios Empresariales, Consumo, Crecimiento Industrial, Sostenibilidad y más. El Panel de Longevidad y Suplementación será accesible a través de livestream en wsw.com/webcast/roth50.
ChromaDex (NASDAQ: CDXC), NAD+ 과학 및 건강한 노화의 선두주자는 제37회 연례 ROTH 컨퍼런스에 참여한다고 발표했습니다. CEO Rob Fried는 3월 17일 월요일 오후 12:00 PT에 장수 및 보충 패널에 등장할 예정입니다.
이번 컨퍼런스는 일대일 회의, 분석가가 선택한 화로 옆 대화, 산업 패널 등 다양한 참여 형식을 포함할 것입니다. CEO Rob Fried와 CFO Ozan Pamir는 행사 기간 동안 기관 투자자와 직접 회의를 진행할 것입니다.
컨퍼런스에서는 의료, 기술, 비즈니스 서비스, 소비자, 산업 성장, 지속 가능성 등 여러 성장 분야에서 약 450개의 민간 및 공공 기업이 소개될 예정입니다. 장수 및 보충 패널은 wsw.com/webcast/roth50에서 라이브 스트리밍으로 접근할 수 있습니다.
ChromaDex (NASDAQ: CDXC), un leader dans la science du NAD+ et le vieillissement en bonne santé, a annoncé sa participation à la 37e Conférence Annuelle ROTH. Le PDG Rob Fried sera présent lors du Panel sur la Longévité et la Supplémentation le lundi 17 mars à 12h00 PT.
La conférence comprendra divers formats d'engagement, tels que des réunions individuelles, des discussions au coin du feu sélectionnées par des analystes et des panels d'industrie. Le PDG Rob Fried et le CFO Ozan Pamir réaliseront des réunions en personne avec des investisseurs institutionnels lors de l'événement.
La conférence mettra en avant environ 450 entreprises privées et publiques dans divers secteurs en croissance, y compris la santé, la technologie, les services aux entreprises, la consommation, la croissance industrielle, la durabilité et plus encore. Le Panel sur la Longévité et la Supplémentation sera accessible via un livestream sur wsw.com/webcast/roth50.
ChromaDex (NASDAQ: CDXC), ein führendes Unternehmen in der NAD+ Wissenschaft und gesunden Alterung, hat seine Teilnahme an der 37. jährlichen ROTH-Konferenz angekündigt. CEO Rob Fried wird am Montag, den 17. März, um 12:00 Uhr PT im Panel für Langlebigkeit und Supplementierung auftreten.
Die Konferenz wird verschiedene Engagement-Formate umfassen, wie z.B. persönliche Meetings, von Analysten ausgewählte Kamin-Gespräche und Branchentafeln. Sowohl CEO Rob Fried als auch CFO Ozan Pamir werden während der Veranstaltung persönliche Meetings mit institutionellen Investoren durchführen.
Die Konferenz wird etwa 450 private und öffentliche Unternehmen aus verschiedenen Wachstumssektoren präsentieren, darunter Gesundheitswesen, Technologie, Unternehmensdienstleistungen, Verbraucher, industrielles Wachstum, Nachhaltigkeit und mehr. Das Panel für Langlebigkeit und Supplementierung wird über einen Livestream unter wsw.com/webcast/roth50 zugänglich sein.
- None.
- None.
ChromaDex CEO, Rob Fried, will participate on the Longevity and Supplementation Panel on Monday, March 17, at 12:00 PM PT (3:00 PM ET). Panels will be livestreamed and available at https://wsw.com/webcast/roth50. Additionally, ChromaDex’s CEO, Rob Fried, and CFO, Ozan Pamir, will attend in-person one-on-one meetings with institutional investors throughout the day.
This year’s event will consist of one-on-one and small group meetings, analyst-selected fireside chats, industry keynotes and panels with executive management attending from approximately 450 private and public companies in a variety of growth sectors, including Business Services, Consumer, Healthcare, Industrial Growth, Insurance, Resources, Sustainability and Technology, Media & Entertainment.
To learn more and submit a registration request, visit https://ibn.fm/Roth2025Registration.
The Longevity and Supplementation Panel will be livestreamed and available at https://wsw.com/webcast/roth50.
For additional information on ChromaDex, visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.
Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.
Niagen® is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in
ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, where copies of press releases, news, and financial information are regularly published.
†Based on the top-selling dietary supplement brands by revenue per the largest
About ROTH:
ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Their full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250311067230/en/
ChromaDex Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
Source: ChromaDex Corporation
FAQ
When is ChromaDex (CDXC) presenting at the ROTH Conference 2025?
How can investors watch ChromaDex's ROTH Conference presentation?
What type of meetings will ChromaDex (CDXC) executives participate in at the ROTH Conference?
How many companies are participating in the 37th Annual ROTH Conference with CDXC?
What sectors will be represented at the ROTH Conference where CDXC is presenting?
